Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:Lenvatinib
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:cancer
hepatocellular carcinoma renal cell carcinoma |
| gptkbp:ATCCode |
gptkb:L01XE29
|
| gptkbp:CASNumber |
417716-92-8
|
| gptkbp:category |
protease inhibitor
antineoplastic agent |
| gptkbp:chemicalFormula |
C21H19ClN4O4
|
| gptkbp:developedBy |
gptkb:Eisai_Co.,_Ltd.
|
| https://www.w3.org/2000/01/rdf-schema#label |
E7080
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:palmar-plantar_erythrodysesthesia
nausea diarrhea fatigue hypertension weight loss proteinuria arthralgia decreased appetite |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:KIT gptkb:VEGFR1 gptkb:VEGFR2 gptkb:RET gptkb:FGFR4 gptkb:FGFR2 gptkb:PDGFRα gptkb:VEGFR3 |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Lenvatinib
|
| gptkbp:bfsLayer |
7
|